The 
and is fully active as an endotoxin (1, 3) .
Biosynthesis
A unique set of enzymes in E. coli has recently been discovered that converts the precursors UDP-G1cNAc, R-3-hydroxymyristoyl-ACP, ATP, CMP-KDO, lauroyl-ACP, and myristoyl-ACP to ReLPS ( Fig. 2 ) (1, (4) (5) (6) (7) (8) (9) . Similar enzymes have been found in other common gram-negative pathogens (10).
The first committed step of endotoxin biosynthesis in E. coli is the acylation of UDP-G1cNAc with R-3-hydroxymyristate ( Fig. 2) , catalyzed by the product of the lpxA gene (1, 4) . UDP-G1cNAc is situated at a metabolic branchpoint, as it is also used for the biogenesis of peptidoglycan ( Fig. 1) (11). R-3-Hydroxymyristoyl-ACP is located at still another branchpoint, as it can be elongated to palmitoyl-ACP and incorporated into glycerophospholipids (12). The central roles of these endotoxin precursors in envelope biogenesis may explain the intriguing observation that at least two genes of ReLPS biosynthesis (lpxA and lpxB, Fig. 2 ) are contained in a complex operon near minute 4 on the E. coli chromosome (13, 14) .
As shown in Fig. 2 , UDP-3-0-(R-3-hydroxymyristoyl)-GlcNAc is deacetylated and then N-acylated with a second R-3-hydroxymyristate moiety (5) to generate the nucleotide, UDP-2,3-diacylglucosamine. Coenzyme A thioesters are not utilized in this pathway (4). As expected from the composition of lipid A, both 0 and N acyltransferase display extreme specificity for R-3-hydroxymyristate (4, 10). UDP-2, is the immediate precursor for the nonreducing unit of lipid A, but some of it is also cleaved by a specific pyrophosphatase to generate lipid X ( Fig. 2 ) (6) . The latter functions as the direct precursor of the reducing end of lipid A. After disaccharide formation catalyzed by the product of the lpxB gene (6, 13) , a specific kinase (7) incorporates the 4-monophosphate, generating the intermediate lipid IVA (Fig. 2) . The latter has some of the bioactivity of endotoxin (15) The mechanisms by which LPS is exported from its site of biosynthesis on the inner surface of the inner membrane to the outer surface of the outer membrane are unknown (1, 20) . Knowledge of the biosynthesis of core and 0-antigen sugars is also incomplete, as reviewed elsewhere (1, 21 These results support the model (shown in Fig. 3 The
Future approaches
As CD14 may function to deliver LPS to its site of action (Fig. 3), and Figure   4 shows that measuring the increase either in mIgM cells (Fig. 4A ) or in x mRNA (Fig. 4B) , the maximum response requires 3 days in the 1B8 cells but only 18 h in the wild-type 70Z/3. When the transcription factors were assayed by gel shift, there was a surprise: Fig. 4C shows that the induction of OTF-2 is normal in 1B8, both in speed and magnitude.
However, the mutant cells have almost lost their ability to activate NF-xB. Normal cells show huge increases in the level of nuclear NF-xB minutes after LPS treatment, but the mutant showed less than 5% of the wild-type levels in nuclear fractions even after 4 h of treatment with LPS. The NF-xB is present at normal levels in the cytoplasm of 1B8, so the defect is clearly in the activation of the factor, not in its production. with probes for t and x. C) Cells were treated with LPS for the indicated times and nuclear extracts were prepared. The presence of nuclear factors was determined by incubation with a 32P-labeled double-stranded oligonucleotide containing either the EB (GGGACTTTC) or octamer sequence (ATT1DCAT), followed by analysis of the complexes formed on nondenaturing polyacrylamide gels. Details of the methods can be found in refs 62 and 63.
of experiments has been designed to identify the kinases in the pathway of LPS activation of NF-xB. Again, the key will be mutants with apparent defects in LPS responsiveness. B) Nuclear extracts were prepared and analyzed to determine the level of the OTF-2 and NF-xB nuclear factors as described in the legend to Fig. 1 and in refs 62 and 63 . 
